Previous 10 | Next 10 |
CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter of...
CAMBRIDGE, Mass., April 24, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, will be partic...
CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of Wendy Dwyer as chief business officer....
Gainers: Estre Ambiental (NASDAQ: ESTR ) +81% . Motif Bio plc (NASDAQ: MTFB ) +71% . Nevro (NYSE: NVRO ) +33% . Electrameccanica Vehicles (NASDAQ: SOLO ) +32% . Dragon Victory International (NASDAQ: LYL ) +21% . Fibrocell Science (NASDAQ: FCSC ) +18% . Amira Nature Foods (NYSE:...
The following slide deck was published by Surface Oncology, Inc. in conjunction with this Read more ...
Surface Oncology (NASDAQ: SURF ): Q4 GAAP EPS of -$0.17. More news on: Surface Oncology, Earnings news and commentary, Healthcare stocks news, , Read more ...
CAMBRIDGE, Mass., March 07, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fourt...
CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, will provide a corpora...
IL-27 is a key regulator of checkpoint protein expression SRF388 believed to be the only anti-IL-27 targeted agent in late-preclinical development Investigational New Drug (IND) submission for SRF388 expected in Q4 2019 CAMBRIDGE, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Surface On...
CAMBRIDGE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of the F. Stephen Hodi, MD to the company...
News, Short Squeeze, Breakout and More Instantly...
Surface Oncology Inc. Company Name:
SURF Stock Symbol:
NASDAQ Market:
Surface Oncology Inc. Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Surface Oncology Inc. (SURF) is expected to report $-0.36 for Q3 2023
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF) (“Surface”), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that both Institutional Shareholder Serv...